- Medical Oncology
- Y90 Radioembolization
- Immunotherapy
- Hepatocellular Carcinoma (HCC)
- Clinical Trials
- Interventional Oncology (IO)
- Cross-Specialty Practice
- Transarterial Chemoembolization (TACE)
- Interventional Radiology (IR)
There are now multiple phase 3 studies on combination transarterial chemoembolization (TACE) and immunotherapy showing a significant benefit over TACE alone. How do these findings change the hepatocellular carcinoma (HCC) treatment algorithm? In this multidisciplinary episode of the BackTable Podcast, Dr. Richard Finn (Medical Oncologist at UCLA) and Dr. Julius Chapiro (Interventional Radiologist at Yale University) join host Dr. Chris Beck to discuss immunotherapy, TACE, emerging trends in HCC treatment, and the future of the field.
This podcast is supported by an educational grant from Guerbet.
Timestamps
Resources
More about this episode
The doctors highlight the importance of high quality clinical data and the pivotal studies shaping current best practices. They explore the role of the different players on the multidisciplinary team and compare the oncologic and radiologic perspectives. Additionally, they discuss the synergy between TACE and immunotherapy, the criteria for selecting appropriate treatments, and the ongoing need for research and collaboration.